
Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Drugs In Development, 2022, provides an overview of the Endometriosis (Women's Health) pipeline landscape.
Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 13, 8, 19, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.
Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Drugs In Development, 2022, provides an overview of the Endometriosis (Women's Health) pipeline landscape.
Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 13, 8, 19, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.
Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
163 Pages
- Introduction
- Global Markets Direct Report Coverage
- Endometriosis – Overview
- Endometriosis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Endometriosis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Endometriosis – Companies Involved in Therapeutics Development
- Abalone Bio Inc
- Aptorum Group Ltd
- Bayer AG
- BCI Pharma SA
- Bol Pharma
- Chugai Pharmaceutical Co Ltd
- Context Therapeutics Inc
- Daewoong Pharmaceutical Co Ltd
- Egret Therapeutics Inc
- Eikonoklastes Therapeutics Inc
- ElexoPharm GmbH
- Endomet Biosciences Inc
- Enteris BioPharma Inc
- Eurofarma Laboratorios SA
- Evestra Inc
- Evotec SE
- Ferring International Center SA
- Forendo Pharma Ltd
- GeneScience Pharmaceuticals Co Ltd
- Hangzhou Metai Pharmaceutical Technology Co Ltd
- Hope Medicine Inc
- Immunitor Inc
- Insud Pharma
- Ironwood Pharmaceuticals Inc
- Jiangsu Hengrui Medicine Co Ltd
- Kissei Pharmaceutical Co Ltd
- Livzon Pharmaceutical Group Co Ltd
- Medibiofarma SL
- Mithra Pharmaceuticals SA
- Mitsubishi Tanabe Pharma Corp
- Myovant Sciences Ltd
- Navad Life Sciences Pte Ltd
- Nippon Shinyaku Co Ltd
- Predictive Therapeutics LLC
- PregLem SA
- SYNG Pharmaceuticals Inc
- Synokem Pharmaceuticals Ltd
- Takeda Pharmaceutical Co Ltd
- Temple Therapeutics BV
- TiumBio Co Ltd
- ValiRx Plc
- Viramal Ltd
- Xbrane Biopharma AB
- Endometriosis – Drug Profiles
- (drospirenone + estetrol) – Drug Profile
- (estradiol + norethindrone acetate + relugolix) – Drug Profile
- ABt-140 – Drug Profile
- AMY-109 – Drug Profile
- BAY-2328065 – Drug Profile
- BAY-2395840 – Drug Profile
- BOLDPo-08 – Drug Profile
- CTX-30916 – Drug Profile
- danazol – Drug Profile
- drospirenone – Drug Profile
- Drug 3 for Endometriosis – Drug Profile
- Drug 4 for Endometriosis – Drug Profile
- Drug to Inhibit C-Jun for Endometriosis – Drug Profile
- DWJ-1483 – Drug Profile
- EC-313 – Drug Profile
- estradiol sulfamate – Drug Profile
- ET-201 – Drug Profile
- FOR-6219 – Drug Profile
- goserelin – Drug Profile
- goserelin acetate – Drug Profile
- GXP-1 – Drug Profile
- HMI-115 – Drug Profile
- IW-3300 – Drug Profile
- leuprolide – Drug Profile
- leuprolide acetate – Drug Profile
- linzagolix choline – Drug Profile
- MBF-251 – Drug Profile
- medroxyprogesterone acetate SR – Drug Profile
- MIA-602 – Drug Profile
- MT-2990 – Drug Profile
- NA-0116 – Drug Profile
- NCE-403 – Drug Profile
- NHP-07 – Drug Profile
- NLS-1 – Drug Profile
- NS-580 – Drug Profile
- P2X4 Antagonist – Drug Profile
- Peptides for Endometriosis – Drug Profile
- progesterone – Drug Profile
- quinagolide ER – Drug Profile
- Recombinant Protein to Agonize PEDF for Women's Health – Drug Profile
- relugolix – Drug Profile
- SHR-7280 – Drug Profile
- Small Molecule 2 for Endometriosis and Chronic Cough – Drug Profile
- Small Molecule to Inhibit Microsomal Prostaglandin E Synthase 1 for Endometriosis – Drug Profile
- Small Molecules for Endometriosis, Idiopathic Pulmonary Fibrosis (IPF) and Metastatic Brain Tumor – Drug Profile
- Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis – Drug Profile
- Small Molecules to Inhibit CSF1R for Breast Cancer and Endometriosis – Drug Profile
- Small Molecules to Inhibit HSD17B1 for Endometriosis – Drug Profile
- SP-012 – Drug Profile
- SR-16234 – Drug Profile
- triptorelin – Drug Profile
- triptorelin acetate SR – Drug Profile
- TTX-334 – Drug Profile
- V-Endo – Drug Profile
- VAL-201 – Drug Profile
- VAL-301 – Drug Profile
- Endometriosis – Dormant Projects
- Endometriosis – Discontinued Products
- Endometriosis – Product Development Milestones
- Featured News & Press Releases
- Oct 26, 2022: Enteris BioPharma announces acceptance of abstract for oral presentation at ASRM 2022 Scientific Congress & Expo
- Jun 17, 2022: Myovant Sciences and Pfizer announce publication in The Lancet of phase 3 SPIRIT 1 and SPIRIT 2 studies of once-daily Relugolix combination therapy in women with endometriosis-associated pain
- Jun 14, 2022: Enteris BioPharma presents data from two clinical studies involving oral formulations of leuprolide at ENDO 2022 Annual Conference
- May 25, 2022: ObsEva presents clinical data on oral GnRH antagonist linzagolix at multiple congresses
- May 09, 2022: Ironwood Pharmaceuticals to present new IW-3300 data at Digestive Disease Week 2022
- May 09, 2022: FDA extends review period for Pfizer-Myovant’s sNDA for Myfembree
- Apr 28, 2022: BioInvent receives milestone payment from Bayer/Hope Medicine licensing agreement
- Apr 12, 2022: Enteris BioPharma announces acceptance of two abstracts for presentation at ENDO 2022 Annual Conference
- Apr 12, 2022: Myovant Sciences and Pfizer provide update on supplemental new drug application for MYFEMBREE for the management of moderate to severe pain associated with endometriosis
- Mar 22, 2022: ObsEva announces additional efficacy results for linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
- Jan 06, 2022: ObsEva announces positive topline results for Linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial in patients with moderate-to-severe endometriosis-associated pain
- Dec 10, 2021: ObsEva hosts symposium and presents clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
- Dec 02, 2021: ObsEva announces symposium and presentation of clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
- Oct 19, 2021: Myovant Sciences and Pfizer present data on Relugolix combination therapy from studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
- Oct 04, 2021: Enteris BioPharma announces successful completion of phase 1 clinical trial of optimized Peptelligence oral leuprolide
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Endometriosis, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Universities/Institutes, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Companies, 2022 (Contd..2)
- Table 8: Products under Development by Universities/Institutes, 2022
- Table 9: Number of Products by Stage and Target, 2022
- Table 10: Number of Products by Stage and Mechanism of Action, 2022
- Table 11: Number of Products by Stage and Route of Administration, 2022
- Table 12: Number of Products by Stage and Molecule Type, 2022
- Table 13: Endometriosis – Pipeline by Abalone Bio Inc, 2022
- Table 14: Endometriosis – Pipeline by Aptorum Group Ltd, 2022
- Table 15: Endometriosis – Pipeline by Bayer AG, 2022
- Table 16: Endometriosis – Pipeline by BCI Pharma SA, 2022
- Table 17: Endometriosis – Pipeline by Bol Pharma, 2022
- Table 18: Endometriosis – Pipeline by Chugai Pharmaceutical Co Ltd, 2022
- Table 19: Endometriosis – Pipeline by Context Therapeutics Inc, 2022
- Table 20: Endometriosis – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Table 21: Endometriosis – Pipeline by Egret Therapeutics Inc, 2022
- Table 22: Endometriosis – Pipeline by Eikonoklastes Therapeutics Inc, 2022
- Table 23: Endometriosis – Pipeline by ElexoPharm GmbH, 2022
- Table 24: Endometriosis – Pipeline by Endomet Biosciences Inc, 2022
- Table 25: Endometriosis – Pipeline by Enteris BioPharma Inc, 2022
- Table 26: Endometriosis – Pipeline by Eurofarma Laboratorios SA, 2022
- Table 27: Endometriosis – Pipeline by Evestra Inc, 2022
- Table 28: Endometriosis – Pipeline by Evotec SE, 2022
- Table 29: Endometriosis – Pipeline by Ferring International Center SA, 2022
- Table 30: Endometriosis – Pipeline by Forendo Pharma Ltd, 2022
- Table 31: Endometriosis – Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
- Table 32: Endometriosis – Pipeline by Hangzhou Metai Pharmaceutical Technology Co Ltd, 2022
- Table 33: Endometriosis – Pipeline by Hope Medicine Inc, 2022
- Table 34: Endometriosis – Pipeline by Immunitor Inc, 2022
- Table 35: Endometriosis – Pipeline by Insud Pharma, 2022
- Table 36: Endometriosis – Pipeline by Ironwood Pharmaceuticals Inc, 2022
- Table 37: Endometriosis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 38: Endometriosis – Pipeline by Kissei Pharmaceutical Co Ltd, 2022
- Table 39: Endometriosis – Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
- Table 40: Endometriosis – Pipeline by Medibiofarma SL, 2022
- Table 41: Endometriosis – Pipeline by Mithra Pharmaceuticals SA, 2022
- Table 42: Endometriosis – Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
- Table 43: Endometriosis – Pipeline by Myovant Sciences Ltd, 2022
- Table 44: Endometriosis – Pipeline by Navad Life Sciences Pte Ltd, 2022
- Table 45: Endometriosis – Pipeline by Nippon Shinyaku Co Ltd, 2022
- Table 46: Endometriosis – Pipeline by Predictive Therapeutics LLC, 2022
- Table 47: Endometriosis – Pipeline by PregLem SA, 2022
- Table 48: Endometriosis – Pipeline by SYNG Pharmaceuticals Inc, 2022
- Table 49: Endometriosis – Pipeline by Synokem Pharmaceuticals Ltd, 2022
- Table 50: Endometriosis – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Table 51: Endometriosis – Pipeline by Temple Therapeutics BV, 2022
- Table 52: Endometriosis – Pipeline by TiumBio Co Ltd, 2022
- Table 53: Endometriosis – Pipeline by ValiRx Plc, 2022
- Table 54: Endometriosis – Pipeline by Viramal Ltd, 2022
- Table 55: Endometriosis – Pipeline by Xbrane Biopharma AB, 2022
- Table 56: Endometriosis – Dormant Projects, 2022
- Table 57: Endometriosis – Dormant Projects, 2022 (Contd..1)
- Table 58: Endometriosis – Dormant Projects, 2022 (Contd..2)
- Table 59: Endometriosis – Dormant Projects, 2022 (Contd..3)
- Table 60: Endometriosis – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Endometriosis, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.